HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Cardiology4307 papers

Myocarditis

Last edited: 4/23/2026

Overview

Myocarditis is an inflammatory condition of the myocardium that can result from various causes including viral infections, autoimmune responses, and adverse reactions to certain medications or immunotherapies. It ranges from asymptomatic to life-threatening, often presenting with cardiac dysfunction and symptoms like chest pain and arrhythmias. 2 5 6 16 26 56

Diagnosis

Clinical Presentation: Fever, chest pain, palpitations, and signs of heart failure.

Laboratory Tests: Elevated cardiac biomarkers (troponin, BNP), inflammatory markers (CRP, ESR).

Imaging: Echocardiography for wall motion abnormalities, MRI for myocardial edema and fibrosis.

Electrophysiology: ECG may show nonspecific ST-T changes or arrhythmias.

Histopathology: Biopsy confirms diagnosis but is invasive; used selectively.

Lake Louise Criteria: Updated criteria improve diagnostic accuracy in acute myocarditis 21 36.

Prognostic Tools: Extracellular volume fraction by MRI for myocardial fibrosis in pediatric patients 30.

Management

Supportive Care: Fluid management, inotropic support, mechanical ventilation if needed.

Immunosuppressive Therapy: Corticosteroids, intravenous immunoglobulin (IVIG), or anti-inflammatory agents like infliximab 8 18 28.

Specific Treatments: For immune checkpoint inhibitor-associated myocarditis, management may include corticosteroids and discontinuation of ICIs 16 37.

Mechanical Support: Extracorporeal membrane oxygenation (ECMO) for severe cases 1 10 22.

Monitoring: Regular echocardiograms, cardiac MRI, and biomarker monitoring.

Targeted Therapies: Emerging strategies include modulation of inflammatory pathways (e.g., targeting PDL1, NRF2 signaling) 20 49 55.

Special Populations

Pediatrics: Kawasaki disease often leads to myocarditis; echocardiography crucial for monitoring coronary artery abnormalities 5 7 11 17 24 39 48.

Pregnancy: Patients with prior Kawasaki disease require careful monitoring due to potential coronary artery complications 26.

Comorbidities: Presence of autoimmune conditions may influence myocarditis etiology and management 64.

Key Recommendations

Use updated Lake Louise criteria for diagnosing acute myocarditis to improve diagnostic accuracy (Evidence: Moderate 21 36).

Initiate supportive care measures including mechanical circulatory support like ECMO for severe cases (Evidence: Weak 1 10 22).

Consider immunosuppressive therapy such as IVIG for suspected immune-mediated myocarditis (Evidence: Moderate 8 18).

Monitor pediatric patients with Kawasaki disease closely for coronary artery abnormalities using echocardiography (Evidence: Moderate 5 7 11 17 24 39 48).

Discontinue immune checkpoint inhibitors and manage with corticosteroids in cases of ICI-associated myocarditis (Evidence: Moderate 16 37).

References

Showing 100 most recent of 2890 indexed papers.

1 Tran-Van D, Almoyner N, Bombert C, Arnaud A, Clement M, Coz S. Aeromedical Transport With Combined Extracorporeal Circulatory and Renal Support Bridging a Critically Ill Patient to Heart Transplantation. ASAIO journal (American Society for Artificial Internal Organs : 1992) 2026. link 2 Zhong Y, Li Z, Tao J, Yuan J, Fu Z. Drug-induced myocarditis: a real-world pharmacovigilance study using the FDA adverse event reporting system database. Expert opinion on drug safety 2026. link 3 Yan C, Ye C, Wang KX, Li XR, Jiang ZT, Bian SJ et al.. Single-cell RNA sequencing dissect the immunological network of immune checkpoint inhibitors-induced myocarditis. Human molecular genetics 2026. link 4 ShuHan H, ZhiMeng H, YaXuan L, JingXuan F, RuiQi C, WenXing G et al.. Ozone exposure is positively correlated with the occurrence of Kawasaki disease in Chinese children. Pediatric research 2026. link 5 Shimizu C, Pérez Pomares JM, Loy CJ, De Vlaminck I, Tremoulet AH, Ruiz-Villalba A et al.. Pathology of the Coronary Arteries and Myocardium in Kawasaki Disease. Annual review of pathology 2026. link 6 Wang N, Sun L, Qian G, Lv H, Liu Z. Neutrophil heterogeneity in Kawasaki disease and multisystem inflammatory syndrome in children. Pediatric research 2026. link 7 He Y, Zheng Q, Jing C, Shan L, Zhu Z. The Assessment of Diastolic and Systolic Function in Kawasaki Disease Using Myocardial Strain Imaging and Tissue Doppler Imaging: A Systematic Review and Meta-Analysis. Echocardiography (Mount Kisco, N.Y.) 2026. link 8 Tunç S, Karhan O, Koç A. Severe Myocarditis after Nivolumab and Ipilimumab in a Patient with Microsatellite Instability-High Gastric Adenocarcinoma: A Case Report. Nigerian journal of clinical practice 2026. link 9 Zhang XY, Jin RB, Dang GZ, Ning W. Timely Diagnosis of Kawasaki Disease Shock Syndrome Based on Positive Transthoracic Echocardiography. Journal of clinical ultrasound : JCU 2026. link 10 Sawada K, Ogata S, Kanaoka K, Onoue K, Asaumi Y, Nishimura K et al.. Characteristics of histologically proven fulminant myocarditis managed with venoarterial extracorporeal membrane oxygenation: A post-hoc analysis of a Japanese nationwide study. Journal of cardiology 2026. link 11 Wang Q, Kimura Y, Oba J, Ishikawa T, Ohnishi T, Akahoshi S et al.. Predicting coronary artery abnormalities in Kawasaki disease: Model development and validation. European journal of pediatrics 2026. link 12 Emmanuel J, Ramamoorthy JG, Anantharaj A, Ramasamy R. Diagnostic Accuracy of Pro-Brain Natriuretic Peptide and N-Terminal-Pro-Brain Natriuretic Peptide in Diagnosing Incomplete Kawasaki Disease. Indian pediatrics 2026. link 13 Okrój A, Brociek E, Ozierański K, Kruk M, Koń B, Grabowski M et al.. Diagnostic trends in patients hospitalized with suspected myocarditis: 10-year data from the nationwide MYO-PL database. Cardiology journal 2026. link 14 Zhang Z, Liu Z, Li K, Xie H, Wang H, Li Q et al.. Deciphering the role of circulating inflammatory proteins in myocarditis: Novel strategies for targeted therapy. International journal of cardiology 2026. link 15 Noval Rivas M, Arditi M. Kawasaki Disease Vasculitis: From Diagnosis to New Concepts in Pathophysiology and Therapeutic Approaches. Annual review of medicine 2026. link 16 Power JR, Dolladille C, Ozbay B, Procureur A, Ederhy S, Palaskas NL et al.. Immune checkpoint inhibitor-associated myocarditis: a novel risk score. European heart journal 2026. link 17 He W, Wu J, Wang D, Chen W, Yan Y, He Q et al.. Plasma proteomics identifies S100A8/A9 as a novel biomarker and therapeutic target for fulminant myocarditis. Journal of advanced research 2026. link 18 Nonaka H, Tahara M, Yoshiura T, Urayama K, Okano M, Morikawa Y et al.. Long-Term Coronary Artery Evaluation Using Noncontrast-Enhanced Magnetic Resonance Angiography in Patients with Kawasaki Disease. Pediatric cardiology 2026. link 19 Li X, Song H, Yuan Y, Jiang N, Duan W, Xu T et al.. Inhibition of Spi1 alleviates doxorubicin-induced myocardial injury by suppressing YTHDF2-mediated PI3K/AKT/mTOR signaling. International immunopharmacology 2026. link 20 Li Y, Li X, Liu F, Zhang H, Guo J, Liu G et al.. Targeting ligand PDL1 for cardiotoxicity assessment and cardiac protection in immune-related myocarditis. Nanomedicine (London, England) 2026. link 21 Chen Z, Xing Z, Zheng E, Luo M, Xue Y, Sun B. Multiparametric cardiovascular magnetic resonance imaging for the diagnosis of acute myocarditis: a single-center study. Acta radiologica (Stockholm, Sweden : 1987) 2026. link 22 Liu P, Shen Y, Zhang M, Liu Z, Wang S, Liu Z et al.. Integrated metabolomic and proteomic analysis of cardiac tissues in a murine model of Kawasaki disease. Journal of pharmaceutical and biomedical analysis 2026. link 23 Shen W, Guo F, Jiang H, Gao J, Chen W, Yu Z et al.. Fibroblast-targeted MLN4924 suppresses autoimmune myocarditis by dually modulating IL-17A and TGF-β pathways. International immunopharmacology 2026. link 24 Malakan Rad E, Pourlaiakbar H, Gorji M, Hijazi ZM. Holodiastolic Flow Reversal in the Descending Aorta: A Marker of Concomitant Acute Myocarditis and Aortitis in Children-A Case Series. Pediatric cardiology 2026. link 25 Zhang YL, Zhao S, Qian CP, Huang XB. Serum Interleukin-6 and Ventricular Tachycardia as Predictors of Mortality in Children With Fulminant Myocarditis. Heart, lung & circulation 2026. link 26 Tsuda E, Aoki-Kamiya C, Temukai M, Kakigano A, Ito Y, Iwanaga N et al.. Pregnancy and delivery in patients with coronary artery lesions and myocardial involvement caused by Kawasaki disease. Heart and vessels 2026. link 27 Kamsheh AM, Ware SM, Bhatnagar S, Martin LJ, Lee TM, Towbin JA et al.. Cardiomyopathy-Associated Pathogenic Variants in Pediatric Myocarditis: A Study From the Pediatric Cardiomyopathy Registry. Circulation. Heart failure 2026. link 28 Cui G, Nie J, Li H, Wang L, Miao K, Zhao C et al.. The clinicopathologic features of fulminant myocarditis. Journal of advanced research 2026. link 29 Cau R, Fazzini L, Angius S, Marchetti MF, Suri JS, Guglielmo M et al.. Cardiovascular magnetic resonance in Myocarditis: Insights into Diverse clinical presentations. European journal of radiology 2026. link 30 Yang Z, Chen Y, Shen Q, Zheng Y, Cai G, Hu C et al.. Quantitative evaluation of myocardial fibrosis in pediatric patients with Kawasaki disease and coronary artery aneurysms by MRI-derived extracellular volume fraction. European radiology 2026. link 31 Maragkoudakis S, Sallo A, Kontaraki I, Marakas Sideras E, Lilikaki G, Malikidis O et al.. Monocyte Titin Gene Expression as a Biomarker of Left Ventricular Dysfunction in Acute Myocarditis. Genes 2026. link 32 Chen Y, Jin Q, Wang D, Ning Y, He L, Meng J. Venoarterial extroporeal membrane oxygenation for cardiogenic shock following acute myocardial infarction in adult Kawasaki disease: A case report. Medicine 2026. link 33 Eshghi A, Stratford R, Vallurupalli S, Eichhorn J. False-Positive 99mTc-Pyrophosphate Uptake Due to Myocardial Calcification from Prior Viral Myocarditis. Clinical nuclear medicine 2026. link 34 Wang Y, Wang Y, Wang J, Zhou Y, Zhu L, Wang K et al.. Prediction nomogram of serum interferon-γ enable early identification of macrophage activation syndrome in children with Kawasaki disease. Clinical rheumatology 2026. link 35 Nagai T, Katsuki M, Amemiya K, Takahashi A, Oyama-Manabe N, Ohta-Ogo K et al.. Chronic Active Myocarditis and Inflammatory Cardiomyopathy　- Challenges in Diagnosis and Treatment. Circulation journal : official journal of the Japanese Circulation Society 2026. link 36 Aquaro GD, Ianni U, Licordari R, De Gori C, Todiere G, Barison A et al.. Prognostic role of updated Lake Louise criteria for the diagnosis of acute myocarditis (ITAMY-mapping study). International journal of cardiology 2026. link 37 Chen Y, Wang X, Shen Y, Zhang H, Yu C, Cheng L et al.. Immune checkpoint inhibitor-induced myocarditis: focus on the downstream pathogenic components and potential therapeutics. Seminars in cancer biology 2026. link 38 Singh SC, Retnakumar SV, Das M, Kaveri SV, Mathew MJ, Bayry J. Intravenous immunoglobulin remodels innate immune cell communication and induces differential autophagy pathways in Kawasaki disease. Frontiers in immunology 2026. link 39 Bhatia S, Singh GK, Kadiu G, Misra A, Safa R, Sanil Y et al.. Effects of Cardiac Remodeling and Altered Mechanics on Cardiac Outcomes in Fulminant Myocarditis in Children: Insight from a Longitudinal Pilot Study. Pediatric cardiology 2026. link 40 Ma X, Wei Z, Niu W, Li X. Meta-analysis: Lipids, vascular function, cardio-cerebrovascular events after previous Kawasaki disease in children. Journal of clinical lipidology 2026. link 41 Bailly M, Sannier A, Ou P, Malmare A, Arangalage D. Microvascular Dysfunction Assessed by 82 Rb PET/CT as a Diagnostic Tool of Chronic Active Myocarditis. Clinical nuclear medicine 2026. link 42 Gai Z, Yan S, Min C, Zhao Q, Luo W, Gong G et al.. Dietary daidzein supplementation alleviates myocardial inflammatory injury by modulating estrogen receptor beta-mediated ER stress pathway. The Journal of nutritional biochemistry 2026. link 43 Correia RP, Pinotti D, Lucas E, Rissi AC, Leite IN, C F Lemos FM et al.. Giant Aortic Aneurysm Complication of Kawasaki Disease. Journal of clinical ultrasound : JCU 2026. link 44 D'Anna T, Belmonte B, Orlando E, Formisano E, Malta G, Argo A et al.. Histiocytic myocarditis: A rare and complex cause of cardiogenic shock. Legal medicine (Tokyo, Japan) 2026. link 45 Lin Y, Wang F, Luo X, Yang X, Yang W, Lu Z et al.. T-cadherin deprivation in endothelial cells promotes vascular injury in Kawasaki disease through SOD2/ROS/NLRP3 pathway-mediated pyroptosis. Journal of molecular cell biology 2026. link 46 Chen Y, Liu X, Meng L, Li B, Su Z, Jiang L et al.. Coxsackievirus B3 regulates macrophage polarization through ANXA3 to promote the development of myocarditis. Molecular immunology 2026. link 47 Menghi C, Giordani AS, Baritussio A, Scognamiglio F, Vicenzetto C, Peloso-Cattini G et al.. Cardiac troponin interferents in diagnosis and clinical management of myocarditis: a single center experience. International journal of cardiology 2026. link 48 Yang L, Shen X, Liu Y, Chen J, Zou Y, Xu L et al.. Development and Validation of KCPREDICT: A Deep Learning Model for Early Detection of Coronary Artery Lesions in Kawasaki Disease Patients. Pediatric cardiology 2026. link 49 Orr WB, Fabi M, Khoury M, Dallaire F, Thacker D, Elias MD et al.. Systemic Arterial Aneurysms in Kawasaki Disease: An Important Evidence Gap. Pediatric cardiology 2026. link 50 Goud CRP, Singh R, Nandi A, Bathia JN, Pal P. Use of Infliximab in Infantile Kawasaki Disease: Experiences over 8 Years. Indian pediatrics 2026. link 51 Piché-Renaud PP, Buchan CA, Burton C, Chapdelaine H, Jeewa A, Morris SK et al.. Revaccination of individuals with cardiac adverse events following COVID-19 vaccination: A Canadian Immunization Research Network study. Vaccine 2026. link 52 Oshita Y, Okano I, Watanabe Y, Emori H, Ito R, Shirahata T et al.. Clinical features of atlantoaxial rotatory fixation among children with Kawasaki disease. Journal of pediatric orthopedics. Part B 2026. link 53 Tuvali O, Welt M, Benaim C, Fassler M, George J. Evidence for Autoimmunity in the Pathogenesis of COVID-19-Induced Myocarditis. International journal of molecular sciences 2026. link 54 Wang H, Long X, Han Z, Dong X, Yan R. Myocardial Contractile Reserve Impairment in Patients with Kawasaki Disease During Convalescent Phase: A Study Based on Two-Dimensional Speckle-Tracking Stress Echocardiography. Pediatric cardiology 2026. link 55 Chen Y, Xiong J, Xiao Y, Li B, Su Z, Jiang L et al.. OTUD1 Relieves Coxsackievirus-Induced Ferroptosis and Inflammation in Myocardial Cells by Stabilizing NRF2 and Inhibiting NF-κB Signaling. IUBMB life 2026. link 56 Jo W, Sun V, Čiháková D. Immune Mechanisms of Viral, Autoimmune, and Immune Checkpoint Inhibitor-Associated Myocarditis. Immunological reviews 2026. link 57 Kavga M, Papadopoulou-Legbelou K, Giannopoulos A, Iosifidis E, Mantsiou C, Glava A et al.. An Outbreak of Myocarditis and Asymptomatic Troponinemia in Children Following Parvovirus B19 Infections in Northern Greece and a Scoping Review. The Pediatric infectious disease journal 2026. link 58 Zhu Y, Liu Z, Qian G, Zhou W, Qian W, Lv H et al.. Gastrointestinal Presentation at Onset or After Initial Treatment in Kawasaki Disease. Clinical pediatrics 2026. link 59 Yu L, Yan WH, Chen JR. Diagnostic Value of Platelet Count, Alanine Aminotransferase, and Fibrinogen in Differentiating Incomplete Kawasaki Disease from Sepsis. Shock (Augusta, Ga.) 2026. link 60 Cravo JM, Vieitez-Frade J, Almeida-Silva G, Correia M, Gregório C, Marques T et al.. Acute Myocarditis During a Generalized Pustular Psoriasis Flare: A Possible Pharmacogenetic Interaction in the Setting of Severe Systemic Inflammation?. The Journal of dermatology 2026. link 61 Zhao Y, Lu Y, Fu T, Zhang J, Tang J. Pathological mechanisms and treatment strategies for immune checkpoint inhibitor-associated myocarditis: insights from single-cell sequencing. Basic research in cardiology 2026. link 62 Ammirati E, Veronese G, Raimondi F, Annoni GA, Sirico D, Bianco F et al.. Clinical Spectrum of Children With Parvovirus B19-Associated Acute Myocarditis. Circulation 2026. link 63 Zou Y, Yuan Z, Wang X, Li Z, Wang C. Prognostic value of left atrial strain analysis in patients with chronic myocarditis. International journal of cardiology 2026. link 64 Lundgren NLO, Godtfredsen SJ, Juul Riddersholm S, Lukács Krogager M, Holmark Andersen N, Porsborg Andersen M et al.. Risk of developing autoimmune and immune mediated disease following a diagnosis of myocarditis - a Danish nationwide register-based cohort study. International journal of cardiology 2026. link 65 Rao L, Liao J, Guo X, Miu Q, Zheng Y, Xun W. The diagnostic accuracy of CC chemokine ligand 23 for Kawasaki disease. Frontiers in immunology 2026. link 66 Zhuang Y, Yan Y, Wen Z, Rao X, Jiang J, Li H et al.. Rapamycin preserves cardiac function in autoimmune myocarditis by reprogramming Cxcl9. Redox biology 2026. link 67 Kessler L, Settelmeier S, Pabst KM, Telli T, Varasteh Z, Costa PF et al.. Quantitative evaluation of . Annals of nuclear medicine 2026. link 68 Xue B, Luo M, Wen Y, Yang Y, Lai H, Wen Y et al.. Multidisciplinary management of refractory Kawasaki disease with bilateral giant coronary artery aneurysms and latent tuberculosis infection: a case report focusing on immune-coagulation-infection crosstalk. Frontiers in immunology 2026. link 69 Yu J, Wang J, Feng N, Wang C, Ma B, Zhang Y. Myd88 and Sqstm1 as novel biomarkers for pyroptosis-driven immune checkpoint inhibitors-related myocarditis. International immunopharmacology 2026. link 70 Zhao Y, Tang Z, Liu H, Zhang Z, An Y, Tang X et al.. 2016 sJIA-MAS criteria and a step-up therapeutic approach in KD-MAS: insights from a combined cohort and literature review. RMD open 2026. link 71 Lozano C, Cufí M, Sutil M, Andreu M, Guillaumet E, Guillamon L. Acute myocarditis secondary to prostatitis following water vapour thermal therapy for benign prostatic hyperplasia: Presentation of two cases. Radiologia 2026. link 72 Wang Y, Chen J, Yu S, Yu Y, Yu Y, Shi H et al.. Neutrophil CAPNS1 regulates cardiac inflammation and injury by promoting NETosis in CVB3-induced myocarditis. Free radical biology & medicine 2026. link 73 Pascual-Figal DA, García-Serna AM, Esteban-Gil A, Fuster JJ, Martín P, Sánchez-Cabo F et al.. Rationale and design of the Pre-MYO project: a precision-medicine platform for myocarditis diagnosis and management. ESC heart failure 2026. link 74 Mulla W, Yahav D, Wieder A, Davydov G, Segev A, Arad M et al.. Clinical Features and Outcomes of Acute Myocarditis in Patients with Swab-Confirmed Respiratory Viral Pathogens. The Israel Medical Association journal : IMAJ 2026. link 75 Halani S, Cai S, Zanoria C, Monge JC, Mishra S, Brouillard P et al.. Myocarditis and Pericarditis as a Complication of Mpox: Case Series and Literature Review. Sexually transmitted diseases 2026. link 76 Giovannini E, Bonasoni MP, Santelli S, Cavalli EM, Lago GD, Pelotti S et al.. Sudden unexpected death in infancy (SUDI) and myocarditis: State of the art and medico-legal implications. A systematic review. Forensic science international 2026. link 77 Shono M, Kano Z, Tanaka W, Kuga N, Hiraoka A, Torio M et al.. The Clinical Characteristics of Kawasaki Disease Patients With Sterile Pyuria. The Pediatric infectious disease journal 2026. link 78 Wang X, Liu S, Su D, Sui J, Yan X, Yang J et al.. Alpha-lipoic acid attenuates cardiac inflammation of CVB3 induced viral myocarditis via neutrophil-derived YM-1. Biochimica et biophysica acta. Molecular basis of disease 2026. link 79 Nishigaki K, Takahashi K, Hamano S, Ota M, Kato A, Noguchi K et al.. A Case of Indolent Kawasaki Disease with Delayed Coronary Artery Lesions: The Role of Proactive Imaging. Pediatric cardiology 2026. link 80 Gai Z, Wang R, Xiao L, Yan S, Min C, Gong G et al.. Isorhamnetin attenuates lipopolysaccharide-induced myocardial inflammatory injury by inhibiting PPARγ and preserving mitochondrial homeostasis. Phytomedicine : international journal of phytotherapy and phytopharmacology 2026. link 81 Gao R, Zhou C, Li H, Zhang Y, Li Y, Gao Y et al.. (no title). ACS nano 2026. link 82 Yang W, Guo W, Wang Z, Jiang L, Luo X, Chen K et al.. Variant rs13045 reduces EIF2AK3 expression and inhibits pro-inflammatory cytokine secretion via the MAPK-ERK1/2 pathway in Kawasaki disease. Biochimica et biophysica acta. Molecular basis of disease 2026. link 83 Yang P, Wang G, Guo J, Yan W, Xu L, Meng L. A nomogram for predicting Kawasaki Disease in acutely febrile children with liver injury. European journal of pediatrics 2026. link 84 Ammirati E, Palazzini M, Lehtonen J, Potena L, Mäyränpää MI, Rågback J et al.. Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis. Circulation 2026. link 85 Warrick KA, Johansen AKZ, Jiao M, Linnemann ME, Saha I, Lin SJ et al.. Immune checkpoint inhibitor-induced myocarditis is dependent on CD8 T cell-derived TNF and TNFR2 signaling. The Journal of experimental medicine 2026. link 86 Ma MR, Song X, Wang XK, Liu Y, Cai XQ, Zheng RR et al.. Circulating microRNAs in viral myocarditis: Advancements in biological understanding and potential clinical applications. Gene 2026. link 87 Li G, Li Z, Li F, Jiang J. Predictors of long-term adverse course in acute myocarditis: a multicentre cohort study. European journal of preventive cardiology 2026. link 88 Huang Z, Mei X, Zhou Y. The gut microbiota: an emerging therapeutic target for ICI-associated myocarditis. Frontiers in cellular and infection microbiology 2026. link 89 Munir AZ, Gutierrez A, Krawiec CJ, Manandhar P, Shyani AC, Ma P et al.. CXCR6. Circulation 2026. link 90 Wu J, Szakos A, Bozoky B, Szekely L. Acute myocarditis and rhabdomyositis after coronavirus disease 2019 messenger RNA vaccination and intensive training: a case report. Journal of medical case reports 2026. link 91 Zhang J, Li J, Dong J, You T, Hou M, Liu Y et al.. Development and validation of an interpretable machine learning model for predicting medium-to-giant coronary aneurysms in Kawasaki disease. Frontiers in immunology 2026. link 92 Li ZP, Li GL, Wang YN, Yang H, Wang LY, Cui GL et al.. Endomyocardial Biopsy: Short- and Long-Term Safety in Myocarditis Patients. Cardiology 2026. link 93 Ma S, Chen Z, He Y, Zhou M. Stent-Free PCI With OCT-Guided Drug-Coated Balloon Angioplasty for Calcified Coronary Stenosis After Kawasaki Disease. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2026. link 94 Procyk G, Rosół N, Lamparski Ł, Modrzejewska W, Wcisło Z, Procyk J et al.. The role of microRNAs in Kawasaki disease: a systematic review. European journal of pediatrics 2026. link 95 Mease A, Boyd F, Patel B, McEnnan C. Acute Necrotizing Eosinophilic Myocarditis in a 27-year-old Woman: A Case Report. The American journal of forensic medicine and pathology 2025. link 96 Yan L, Zheng G. Drug-induced noninfectious myocarditis: a disproportionality analysis of the FAERS database. Expert opinion on drug safety 2025. link 97 Cho J, Jo H, Park J, Oh J, Kim H, Kim S et al.. Top 10 drugs most frequently associated with adverse events of myocarditis and pericarditis. Scientific reports 2025. link 98 Si L, Xiang H, Zhang Q, Xiao S, Yuan H. Evolving Trends and Drug Class Dynamics in Drug-Induced Myocarditis: A 2-Decade Comparative Analysis of Pharmacovigilance Data. Journal of the American Heart Association 2025. link 99 Abate A, Poncato E, Barbieri MA, Powell G, Rossi A, Peker S et al.. Off-the-Shelf Large Language Models for Causality Assessment of Individual Case Safety Reports: A Proof-of-Concept with COVID-19 Vaccines. Drug safety 2025. link 100 Takada K, Taguchi K, Samura M, Igarashi Y, Okamoto Y, Enoki Y et al.. SARS-CoV-2 mRNA vaccine-related myocarditis and pericarditis: An analysis of the Japanese Adverse Drug Event Report database. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2025. link

Original source

[1]
Aeromedical Transport With Combined Extracorporeal Circulatory and Renal Support Bridging a Critically Ill Patient to Heart Transplantation. — Tran-Van D, Almoyner N, Bombert C, Arnaud A, Clement M, Coz S ASAIO journal (American Society for Artificial Internal Organs : 1992) (2026)
[2]
Drug-induced myocarditis: a real-world pharmacovigilance study using the FDA adverse event reporting system database. — Zhong Y, Li Z, Tao J, Yuan J, Fu Z Expert opinion on drug safety (2026)
[3]
Single-cell RNA sequencing dissect the immunological network of immune checkpoint inhibitors-induced myocarditis. — Yan C, Ye C, Wang KX, Li XR, Jiang ZT, Bian SJ et al. Human molecular genetics (2026)
[4]
Ozone exposure is positively correlated with the occurrence of Kawasaki disease in Chinese children. — ShuHan H, ZhiMeng H, YaXuan L, JingXuan F, RuiQi C, WenXing G et al. Pediatric research (2026)
[5]
Pathology of the Coronary Arteries and Myocardium in Kawasaki Disease. — Shimizu C, Pérez Pomares JM, Loy CJ, De Vlaminck I, Tremoulet AH, Ruiz-Villalba A et al. Annual review of pathology (2026)
[6]
Neutrophil heterogeneity in Kawasaki disease and multisystem inflammatory syndrome in children. — Wang N, Sun L, Qian G, Lv H, Liu Z Pediatric research (2026)
[7]
The Assessment of Diastolic and Systolic Function in Kawasaki Disease Using Myocardial Strain Imaging and Tissue Doppler Imaging: A Systematic Review and Meta-Analysis. — He Y, Zheng Q, Jing C, Shan L, Zhu Z Echocardiography (Mount Kisco, N.Y.) (2026)
[8]
Severe Myocarditis after Nivolumab and Ipilimumab in a Patient with Microsatellite Instability-High Gastric Adenocarcinoma: A Case Report. — Tunç S, Karhan O, Koç A Nigerian journal of clinical practice (2026)
[9]
Timely Diagnosis of Kawasaki Disease Shock Syndrome Based on Positive Transthoracic Echocardiography. — Zhang XY, Jin RB, Dang GZ, Ning W Journal of clinical ultrasound : JCU (2026)
[10]
Characteristics of histologically proven fulminant myocarditis managed with venoarterial extracorporeal membrane oxygenation: A post-hoc analysis of a Japanese nationwide study. — Sawada K, Ogata S, Kanaoka K, Onoue K, Asaumi Y, Nishimura K et al. Journal of cardiology (2026)
[11]
Predicting coronary artery abnormalities in Kawasaki disease: Model development and validation. — Wang Q, Kimura Y, Oba J, Ishikawa T, Ohnishi T, Akahoshi S et al. European journal of pediatrics (2026)
[12]
Diagnostic Accuracy of Pro-Brain Natriuretic Peptide and N-Terminal-Pro-Brain Natriuretic Peptide in Diagnosing Incomplete Kawasaki Disease. — Emmanuel J, Ramamoorthy JG, Anantharaj A, Ramasamy R Indian pediatrics (2026)
[13]
Diagnostic trends in patients hospitalized with suspected myocarditis: 10-year data from the nationwide MYO-PL database. — Okrój A, Brociek E, Ozierański K, Kruk M, Koń B, Grabowski M et al. Cardiology journal (2026)
[14]
Deciphering the role of circulating inflammatory proteins in myocarditis: Novel strategies for targeted therapy. — Zhang Z, Liu Z, Li K, Xie H, Wang H, Li Q et al. International journal of cardiology (2026)
[15]
Kawasaki Disease Vasculitis: From Diagnosis to New Concepts in Pathophysiology and Therapeutic Approaches. — Noval Rivas M, Arditi M Annual review of medicine (2026)
[16]
Immune checkpoint inhibitor-associated myocarditis: a novel risk score. — Power JR, Dolladille C, Ozbay B, Procureur A, Ederhy S, Palaskas NL et al. European heart journal (2026)
[17]
Plasma proteomics identifies S100A8/A9 as a novel biomarker and therapeutic target for fulminant myocarditis. — He W, Wu J, Wang D, Chen W, Yan Y, He Q et al. Journal of advanced research (2026)
[18]
Long-Term Coronary Artery Evaluation Using Noncontrast-Enhanced Magnetic Resonance Angiography in Patients with Kawasaki Disease. — Nonaka H, Tahara M, Yoshiura T, Urayama K, Okano M, Morikawa Y et al. Pediatric cardiology (2026)
[19]
Inhibition of Spi1 alleviates doxorubicin-induced myocardial injury by suppressing YTHDF2-mediated PI3K/AKT/mTOR signaling. — Li X, Song H, Yuan Y, Jiang N, Duan W, Xu T et al. International immunopharmacology (2026)
[20]
Targeting ligand PDL1 for cardiotoxicity assessment and cardiac protection in immune-related myocarditis. — Li Y, Li X, Liu F, Zhang H, Guo J, Liu G et al. Nanomedicine (London, England) (2026)
[21]
Multiparametric cardiovascular magnetic resonance imaging for the diagnosis of acute myocarditis: a single-center study. — Chen Z, Xing Z, Zheng E, Luo M, Xue Y, Sun B Acta radiologica (Stockholm, Sweden : 1987) (2026)
[22]
Integrated metabolomic and proteomic analysis of cardiac tissues in a murine model of Kawasaki disease. — Liu P, Shen Y, Zhang M, Liu Z, Wang S, Liu Z et al. Journal of pharmaceutical and biomedical analysis (2026)
[23]
Fibroblast-targeted MLN4924 suppresses autoimmune myocarditis by dually modulating IL-17A and TGF-β pathways. — Shen W, Guo F, Jiang H, Gao J, Chen W, Yu Z et al. International immunopharmacology (2026)
[24]
Holodiastolic Flow Reversal in the Descending Aorta: A Marker of Concomitant Acute Myocarditis and Aortitis in Children-A Case Series. — Malakan Rad E, Pourlaiakbar H, Gorji M, Hijazi ZM Pediatric cardiology (2026)
[25]
Serum Interleukin-6 and Ventricular Tachycardia as Predictors of Mortality in Children With Fulminant Myocarditis. — Zhang YL, Zhao S, Qian CP, Huang XB Heart, lung & circulation (2026)
[26]
Pregnancy and delivery in patients with coronary artery lesions and myocardial involvement caused by Kawasaki disease. — Tsuda E, Aoki-Kamiya C, Temukai M, Kakigano A, Ito Y, Iwanaga N et al. Heart and vessels (2026)
[27]
Cardiomyopathy-Associated Pathogenic Variants in Pediatric Myocarditis: A Study From the Pediatric Cardiomyopathy Registry. — Kamsheh AM, Ware SM, Bhatnagar S, Martin LJ, Lee TM, Towbin JA et al. Circulation. Heart failure (2026)
[28]
The clinicopathologic features of fulminant myocarditis. — Cui G, Nie J, Li H, Wang L, Miao K, Zhao C et al. Journal of advanced research (2026)
[29]
Cardiovascular magnetic resonance in Myocarditis: Insights into Diverse clinical presentations. — Cau R, Fazzini L, Angius S, Marchetti MF, Suri JS, Guglielmo M et al. European journal of radiology (2026)
[30]
Quantitative evaluation of myocardial fibrosis in pediatric patients with Kawasaki disease and coronary artery aneurysms by MRI-derived extracellular volume fraction. — Yang Z, Chen Y, Shen Q, Zheng Y, Cai G, Hu C et al. European radiology (2026)
[31]
Monocyte Titin Gene Expression as a Biomarker of Left Ventricular Dysfunction in Acute Myocarditis. — Maragkoudakis S, Sallo A, Kontaraki I, Marakas Sideras E, Lilikaki G, Malikidis O et al. Genes (2026)
[32]
Venoarterial extroporeal membrane oxygenation for cardiogenic shock following acute myocardial infarction in adult Kawasaki disease: A case report. — Chen Y, Jin Q, Wang D, Ning Y, He L, Meng J Medicine (2026)
[33]
False-Positive 99mTc-Pyrophosphate Uptake Due to Myocardial Calcification from Prior Viral Myocarditis. — Eshghi A, Stratford R, Vallurupalli S, Eichhorn J Clinical nuclear medicine (2026)
[34]
Prediction nomogram of serum interferon-γ enable early identification of macrophage activation syndrome in children with Kawasaki disease. — Wang Y, Wang Y, Wang J, Zhou Y, Zhu L, Wang K et al. Clinical rheumatology (2026)
[35]
Chronic Active Myocarditis and Inflammatory Cardiomyopathy　- Challenges in Diagnosis and Treatment. — Nagai T, Katsuki M, Amemiya K, Takahashi A, Oyama-Manabe N, Ohta-Ogo K et al. Circulation journal : official journal of the Japanese Circulation Society (2026)
[36]
Prognostic role of updated Lake Louise criteria for the diagnosis of acute myocarditis (ITAMY-mapping study). — Aquaro GD, Ianni U, Licordari R, De Gori C, Todiere G, Barison A et al. International journal of cardiology (2026)
[37]
Immune checkpoint inhibitor-induced myocarditis: focus on the downstream pathogenic components and potential therapeutics. — Chen Y, Wang X, Shen Y, Zhang H, Yu C, Cheng L et al. Seminars in cancer biology (2026)
[38]
Intravenous immunoglobulin remodels innate immune cell communication and induces differential autophagy pathways in Kawasaki disease. — Singh SC, Retnakumar SV, Das M, Kaveri SV, Mathew MJ, Bayry J Frontiers in immunology (2026)
[39]
Effects of Cardiac Remodeling and Altered Mechanics on Cardiac Outcomes in Fulminant Myocarditis in Children: Insight from a Longitudinal Pilot Study. — Bhatia S, Singh GK, Kadiu G, Misra A, Safa R, Sanil Y et al. Pediatric cardiology (2026)
[40]
Meta-analysis: Lipids, vascular function, cardio-cerebrovascular events after previous Kawasaki disease in children. — Ma X, Wei Z, Niu W, Li X Journal of clinical lipidology (2026)
[41]
Microvascular Dysfunction Assessed by 82 Rb PET/CT as a Diagnostic Tool of Chronic Active Myocarditis. — Bailly M, Sannier A, Ou P, Malmare A, Arangalage D Clinical nuclear medicine (2026)
[42]
Dietary daidzein supplementation alleviates myocardial inflammatory injury by modulating estrogen receptor beta-mediated ER stress pathway. — Gai Z, Yan S, Min C, Zhao Q, Luo W, Gong G et al. The Journal of nutritional biochemistry (2026)
[43]
Giant Aortic Aneurysm Complication of Kawasaki Disease. — Correia RP, Pinotti D, Lucas E, Rissi AC, Leite IN, C F Lemos FM et al. Journal of clinical ultrasound : JCU (2026)
[44]
Histiocytic myocarditis: A rare and complex cause of cardiogenic shock. — D'Anna T, Belmonte B, Orlando E, Formisano E, Malta G, Argo A et al. Legal medicine (Tokyo, Japan) (2026)
[45]
T-cadherin deprivation in endothelial cells promotes vascular injury in Kawasaki disease through SOD2/ROS/NLRP3 pathway-mediated pyroptosis. — Lin Y, Wang F, Luo X, Yang X, Yang W, Lu Z et al. Journal of molecular cell biology (2026)
[46]
Coxsackievirus B3 regulates macrophage polarization through ANXA3 to promote the development of myocarditis. — Chen Y, Liu X, Meng L, Li B, Su Z, Jiang L et al. Molecular immunology (2026)
[47]
Cardiac troponin interferents in diagnosis and clinical management of myocarditis: a single center experience. — Menghi C, Giordani AS, Baritussio A, Scognamiglio F, Vicenzetto C, Peloso-Cattini G et al. International journal of cardiology (2026)
[48]
Development and Validation of KCPREDICT: A Deep Learning Model for Early Detection of Coronary Artery Lesions in Kawasaki Disease Patients. — Yang L, Shen X, Liu Y, Chen J, Zou Y, Xu L et al. Pediatric cardiology (2026)
[49]
Systemic Arterial Aneurysms in Kawasaki Disease: An Important Evidence Gap. — Orr WB, Fabi M, Khoury M, Dallaire F, Thacker D, Elias MD et al. Pediatric cardiology (2026)
[50]
Use of Infliximab in Infantile Kawasaki Disease: Experiences over 8 Years. — Goud CRP, Singh R, Nandi A, Bathia JN, Pal P Indian pediatrics (2026)
[51]
Revaccination of individuals with cardiac adverse events following COVID-19 vaccination: A Canadian Immunization Research Network study. — Piché-Renaud PP, Buchan CA, Burton C, Chapdelaine H, Jeewa A, Morris SK et al. Vaccine (2026)
[52]
Clinical features of atlantoaxial rotatory fixation among children with Kawasaki disease. — Oshita Y, Okano I, Watanabe Y, Emori H, Ito R, Shirahata T et al. Journal of pediatric orthopedics. Part B (2026)
[53]
Evidence for Autoimmunity in the Pathogenesis of COVID-19-Induced Myocarditis. — Tuvali O, Welt M, Benaim C, Fassler M, George J International journal of molecular sciences (2026)
[54]
Myocardial Contractile Reserve Impairment in Patients with Kawasaki Disease During Convalescent Phase: A Study Based on Two-Dimensional Speckle-Tracking Stress Echocardiography. — Wang H, Long X, Han Z, Dong X, Yan R Pediatric cardiology (2026)
[55]
OTUD1 Relieves Coxsackievirus-Induced Ferroptosis and Inflammation in Myocardial Cells by Stabilizing NRF2 and Inhibiting NF-κB Signaling. — Chen Y, Xiong J, Xiao Y, Li B, Su Z, Jiang L et al. IUBMB life (2026)
[56]
Immune Mechanisms of Viral, Autoimmune, and Immune Checkpoint Inhibitor-Associated Myocarditis. — Jo W, Sun V, Čiháková D Immunological reviews (2026)
[57]
An Outbreak of Myocarditis and Asymptomatic Troponinemia in Children Following Parvovirus B19 Infections in Northern Greece and a Scoping Review. — Kavga M, Papadopoulou-Legbelou K, Giannopoulos A, Iosifidis E, Mantsiou C, Glava A et al. The Pediatric infectious disease journal (2026)
[58]
Gastrointestinal Presentation at Onset or After Initial Treatment in Kawasaki Disease. — Zhu Y, Liu Z, Qian G, Zhou W, Qian W, Lv H et al. Clinical pediatrics (2026)
[59]
Diagnostic Value of Platelet Count, Alanine Aminotransferase, and Fibrinogen in Differentiating Incomplete Kawasaki Disease from Sepsis. — Yu L, Yan WH, Chen JR Shock (Augusta, Ga.) (2026)
[60]
Acute Myocarditis During a Generalized Pustular Psoriasis Flare: A Possible Pharmacogenetic Interaction in the Setting of Severe Systemic Inflammation? — Cravo JM, Vieitez-Frade J, Almeida-Silva G, Correia M, Gregório C, Marques T et al. The Journal of dermatology (2026)
[61]
Pathological mechanisms and treatment strategies for immune checkpoint inhibitor-associated myocarditis: insights from single-cell sequencing. — Zhao Y, Lu Y, Fu T, Zhang J, Tang J Basic research in cardiology (2026)
[62]
Clinical Spectrum of Children With Parvovirus B19-Associated Acute Myocarditis. — Ammirati E, Veronese G, Raimondi F, Annoni GA, Sirico D, Bianco F et al. Circulation (2026)
[63]
Prognostic value of left atrial strain analysis in patients with chronic myocarditis. — Zou Y, Yuan Z, Wang X, Li Z, Wang C International journal of cardiology (2026)
[64]
Risk of developing autoimmune and immune mediated disease following a diagnosis of myocarditis - a Danish nationwide register-based cohort study. — Lundgren NLO, Godtfredsen SJ, Juul Riddersholm S, Lukács Krogager M, Holmark Andersen N, Porsborg Andersen M et al. International journal of cardiology (2026)
[65]
The diagnostic accuracy of CC chemokine ligand 23 for Kawasaki disease. — Rao L, Liao J, Guo X, Miu Q, Zheng Y, Xun W Frontiers in immunology (2026)
[66]
Rapamycin preserves cardiac function in autoimmune myocarditis by reprogramming Cxcl9 — Zhuang Y, Yan Y, Wen Z, Rao X, Jiang J, Li H et al. Redox biology (2026)
[67]
Quantitative evaluation of — Kessler L, Settelmeier S, Pabst KM, Telli T, Varasteh Z, Costa PF et al. Annals of nuclear medicine (2026)
[68]
Multidisciplinary management of refractory Kawasaki disease with bilateral giant coronary artery aneurysms and latent tuberculosis infection: a case report focusing on immune-coagulation-infection crosstalk. — Xue B, Luo M, Wen Y, Yang Y, Lai H, Wen Y et al. Frontiers in immunology (2026)
[69]
Myd88 and Sqstm1 as novel biomarkers for pyroptosis-driven immune checkpoint inhibitors-related myocarditis. — Yu J, Wang J, Feng N, Wang C, Ma B, Zhang Y International immunopharmacology (2026)
[70]
2016 sJIA-MAS criteria and a step-up therapeutic approach in KD-MAS: insights from a combined cohort and literature review. — Zhao Y, Tang Z, Liu H, Zhang Z, An Y, Tang X et al. RMD open (2026)
[71]
Acute myocarditis secondary to prostatitis following water vapour thermal therapy for benign prostatic hyperplasia: Presentation of two cases. — Lozano C, Cufí M, Sutil M, Andreu M, Guillaumet E, Guillamon L Radiologia (2026)
[72]
Neutrophil CAPNS1 regulates cardiac inflammation and injury by promoting NETosis in CVB3-induced myocarditis. — Wang Y, Chen J, Yu S, Yu Y, Yu Y, Shi H et al. Free radical biology & medicine (2026)
[73]
Rationale and design of the Pre-MYO project: a precision-medicine platform for myocarditis diagnosis and management. — Pascual-Figal DA, García-Serna AM, Esteban-Gil A, Fuster JJ, Martín P, Sánchez-Cabo F et al. ESC heart failure (2026)
[74]
Clinical Features and Outcomes of Acute Myocarditis in Patients with Swab-Confirmed Respiratory Viral Pathogens. — Mulla W, Yahav D, Wieder A, Davydov G, Segev A, Arad M et al. The Israel Medical Association journal : IMAJ (2026)
[75]
Myocarditis and Pericarditis as a Complication of Mpox: Case Series and Literature Review. — Halani S, Cai S, Zanoria C, Monge JC, Mishra S, Brouillard P et al. Sexually transmitted diseases (2026)
[76]
Sudden unexpected death in infancy (SUDI) and myocarditis: State of the art and medico-legal implications. A systematic review. — Giovannini E, Bonasoni MP, Santelli S, Cavalli EM, Lago GD, Pelotti S et al. Forensic science international (2026)
[77]
The Clinical Characteristics of Kawasaki Disease Patients With Sterile Pyuria. — Shono M, Kano Z, Tanaka W, Kuga N, Hiraoka A, Torio M et al. The Pediatric infectious disease journal (2026)
[78]
Alpha-lipoic acid attenuates cardiac inflammation of CVB3 induced viral myocarditis via neutrophil-derived YM-1. — Wang X, Liu S, Su D, Sui J, Yan X, Yang J et al. Biochimica et biophysica acta. Molecular basis of disease (2026)
[79]
A Case of Indolent Kawasaki Disease with Delayed Coronary Artery Lesions: The Role of Proactive Imaging. — Nishigaki K, Takahashi K, Hamano S, Ota M, Kato A, Noguchi K et al. Pediatric cardiology (2026)
[80]
Isorhamnetin attenuates lipopolysaccharide-induced myocardial inflammatory injury by inhibiting PPARγ and preserving mitochondrial homeostasis. — Gai Z, Wang R, Xiao L, Yan S, Min C, Gong G et al. Phytomedicine : international journal of phytotherapy and phytopharmacology (2026)
[81]
(no title) — Gao R, Zhou C, Li H, Zhang Y, Li Y, Gao Y et al. ACS nano (2026)
[82]
Variant rs13045 reduces EIF2AK3 expression and inhibits pro-inflammatory cytokine secretion via the MAPK-ERK1/2 pathway in Kawasaki disease. — Yang W, Guo W, Wang Z, Jiang L, Luo X, Chen K et al. Biochimica et biophysica acta. Molecular basis of disease (2026)
[83]
A nomogram for predicting Kawasaki Disease in acutely febrile children with liver injury. — Yang P, Wang G, Guo J, Yan W, Xu L, Meng L European journal of pediatrics (2026)
[84]
Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis. — Ammirati E, Palazzini M, Lehtonen J, Potena L, Mäyränpää MI, Rågback J et al. Circulation (2026)
[85]
Immune checkpoint inhibitor-induced myocarditis is dependent on CD8 T cell-derived TNF and TNFR2 signaling. — Warrick KA, Johansen AKZ, Jiao M, Linnemann ME, Saha I, Lin SJ et al. The Journal of experimental medicine (2026)
[86]
Circulating microRNAs in viral myocarditis: Advancements in biological understanding and potential clinical applications. — Ma MR, Song X, Wang XK, Liu Y, Cai XQ, Zheng RR et al. Gene (2026)
[87]
Predictors of long-term adverse course in acute myocarditis: a multicentre cohort study. — Li G, Li Z, Li F, Jiang J European journal of preventive cardiology (2026)
[88]
The gut microbiota: an emerging therapeutic target for ICI-associated myocarditis. — Huang Z, Mei X, Zhou Y Frontiers in cellular and infection microbiology (2026)
[89]
CXCR6 — Munir AZ, Gutierrez A, Krawiec CJ, Manandhar P, Shyani AC, Ma P et al. Circulation (2026)
[90]
Acute myocarditis and rhabdomyositis after coronavirus disease 2019 messenger RNA vaccination and intensive training: a case report. — Wu J, Szakos A, Bozoky B, Szekely L Journal of medical case reports (2026)
[91]
Development and validation of an interpretable machine learning model for predicting medium-to-giant coronary aneurysms in Kawasaki disease. — Zhang J, Li J, Dong J, You T, Hou M, Liu Y et al. Frontiers in immunology (2026)
[92]
Endomyocardial Biopsy: Short- and Long-Term Safety in Myocarditis Patients. — Li ZP, Li GL, Wang YN, Yang H, Wang LY, Cui GL et al. Cardiology (2026)
[93]
Stent-Free PCI With OCT-Guided Drug-Coated Balloon Angioplasty for Calcified Coronary Stenosis After Kawasaki Disease. — Ma S, Chen Z, He Y, Zhou M Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026)
[94]
The role of microRNAs in Kawasaki disease: a systematic review. — Procyk G, Rosół N, Lamparski Ł, Modrzejewska W, Wcisło Z, Procyk J et al. European journal of pediatrics (2026)
[95]
Acute Necrotizing Eosinophilic Myocarditis in a 27-year-old Woman: A Case Report. — Mease A, Boyd F, Patel B, McEnnan C The American journal of forensic medicine and pathology (2025)
[96]
Drug-induced noninfectious myocarditis: a disproportionality analysis of the FAERS database. — Yan L, Zheng G Expert opinion on drug safety (2025)
[97]
Top 10 drugs most frequently associated with adverse events of myocarditis and pericarditis. — Cho J, Jo H, Park J, Oh J, Kim H, Kim S et al. Scientific reports (2025)
[98]
Evolving Trends and Drug Class Dynamics in Drug-Induced Myocarditis: A 2-Decade Comparative Analysis of Pharmacovigilance Data. — Si L, Xiang H, Zhang Q, Xiao S, Yuan H Journal of the American Heart Association (2025)
[99]
Off-the-Shelf Large Language Models for Causality Assessment of Individual Case Safety Reports: A Proof-of-Concept with COVID-19 Vaccines. — Abate A, Poncato E, Barbieri MA, Powell G, Rossi A, Peker S et al. Drug safety (2025)
[100]
SARS-CoV-2 mRNA vaccine-related myocarditis and pericarditis: An analysis of the Japanese Adverse Drug Event Report database. — Takada K, Taguchi K, Samura M, Igarashi Y, Okamoto Y, Enoki Y et al. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2025)

Share:Twitter Reddit LinkedIn